Introduction {#s1}
============

Osteoporosis as a chronic and long-term skeletal disorder is more common in senile people (in men after age 65 and women after age 55 years) ([@B1]--[@B4]). Accordingly, it is responsible for most of the elderly fractures through decreasing the bone mass and mineral density (BMD) ([@B1], [@B5], [@B6]). Moreover, it has been reported that osteoporosis occurs when there is an imbalance between bone cells function ([@B7], [@B8]). In 1993, osteoporosis is defined as "progressive systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture" by WHO ([@B9]--[@B12]). The proximal ends of the humerus and femur, the distal end of the radius, and the vertebral column are more susceptible to the osteoporotic fractures in contrast to other parts of the bone ([@B13]--[@B15]). Additionally, the hip fracture can be considered as the serious complication with high morbidity and mortality ([@B15]--[@B17]). Given the fact that the life expectancy universally is increasing and subsequently osteoporosis becomes a growing global problem with a great impact on quality of life, selecting powerful approaches for disease managing is essential. In this respect, there is no practical pharmaceutical cure ([@B18]). Recently, stem cell therapies have attained remarkable clinical consideration with a promising strategy for regenerative medicine and tissue engineering to treat various types of diseases including osteoporosis ([@B19]--[@B26]). Herein, discuss the effects of stem cell-based therapies in osteoporosis is the main objective of this review.

Bone Biology; Signaling Pathways; Bone Modeling and Remodeling {#s2}
==============================================================

Bone as a highly dynamic tissue continuously undergoes modeling and remodeling via activation of bone cells (osteoblasts, osteoclast, and osteocytes) ([Figure 1](#F1){ref-type="fig"}) ([@B40]--[@B42]). Herein, modeling is defined as separately happening of bone formation and resorption on the bone surface and remodeling is known as the coupling between bone formation and resorption for regeneration ([@B43]--[@B46]). The process of developing new bone material by osteoblasts is called bone formation (ossification or osteogenesis) which commences about 6 weeks after fertilization in embryos. There are two types of bone formation, including intramembranous and endochondral ([@B27], [@B47]). During intramembranous bone formation, mesenchymal stem cells (MSCs) are proliferated and differentiated into osteoblasts in areas of embryonic connective tissue which contain high vascularization. Additionally, the intramembranous bone formation that is involved in the formation of the flat bones of the clavicles, skull, and the mandible is known as a procedure of bone formation from fibrous membranes ([@B48], [@B49]). The endochondral bone formation is befallen at three sites including the physis, the epiphysis, and the cuboidal bones of the carpus and tarsus. It is a procedure in which the cartilage is commonly replaced by bone for the formation of the growing skeleton ([@B50]--[@B52]). In general, bone formation is controlled by various growth factors, cytokines, and hormones ([@B40], [@B53], [@B54]). Therein, osteoblasts can reply to these external signals through various signaling pathways and control the specific gene expression for cell fate determining ([@B28], [@B29], [@B55]). Accordingly, there are some signaling molecules with critical roles in osteoblast turnover including runt-related transcription factor 2 (Runx2), osterix (Osx), ß-Catenin, activating transcription factor 4 (Atf4), and activator protein 1(AP-1) family. Indeed, they have momentous roles in osteoblast differentiation and osteoblastogenesis to promote bone formation ([@B27]--[@B33]). Moreover, it has been demonstrated that fibroblast growth factors (FGFs), transforming growth factor β (TGF β), insulin-like growth factor 1 (IGF-1), bone morphogenetic proteins (BMPs), Notch, Wnt, and parathyroid hormone (PTH) have effective roles in the bone formation process ([@B56]--[@B59]). Bone formation and resorption must be balanced for bone mass maintenance ([@B34], [@B38], [@B39]). Bone resorption is the process of minerals dissolution and organic matrix degradation by osteoclasts, which depends on the osteoclasts secretions into the extracellular space ([@B60]--[@B63]). Some more important types of osteoclasts secretions are lysosomal enzymes (e.g., cathepsin K) and matrix metallopeptidase 9 (MMP-9) ([@B41], [@B64], [@B65]). Osteoclasts arise from the hematopoietic stem cells (HSC) via stimulation of receptor activation of NF-κB ligand (RANKL) and the monocyte/macrophage colony-stimulating factor (M-CSF) from osteoblasts membrane surface ([@B60], [@B66], [@B67]). RANKL and M-CSF are interacted with their receptors present on osteoclast precursors to stimulate osteoclast proliferation and differentiation ([@B60], [@B68], [@B69]). However, there is another signaling molecule called osteoprotegerin (OPG) which is also secreted by osteoblasts to interfere with the RANKL for inhibition of osteoclastogenesis ([@B70]--[@B73]). According to investigations, some inflammatory cytokines e.g., interleukin1 (IL-1), interlukin-6 (IL-6), and tumor necrosis factor-α (TNFα) can be involved in osteoclast differentiation and function ([@B34]--[@B37]). Several findings have indicated that imbalance between osteoclasts and osteoblasts functions can lead to some skeletal disorders including osteoporosis. In fact, these disorders are the consequence of decreased in osteoblast activity and/or increased in osteoclast activity ([@B8], [@B41]).

![Normal Bone Biology; Signaling Pathways. Bone as a dynamic tissue undergoes modeling and remodeling by activation of osteoblasts, osteoclast, and osteocytes. Mesenchymal stem cells (MSCs) are proliferated and differentiated into osteoblasts. Some signaling molecules have important roles in osteoblast turnover and function including runt-related transcription factor 2 (Runx2), osterix (Osx), ß-Catenin, activating transcription factor 4(Atf4), activator protein 1(AP-1) family, fibroblast growth factors (FGFs), transforming growth factor β (TGF β), insulin-like growth factor 1 (IGF-1), bone morphogenetic proteins (BMPs), Notch, Wnt, and parathyroid hormone (PTH) ([@B27]--[@B33]). Osteoblasts which are trapped in the bone matrix are called osteocytes. Osteoclasts are derived from the hematopoietic stem cells (HSC) through the stimulation by receptor activation of NF-κB ligand (RANKL) from osteoblasts. Osteoprotegerin (OPG) which is also secreted by osteoblasts can interfere with the RANKL and inhibit osteoclastogenesis. Osteoclasts can secrete cathepsin K and matrix metallopeptidase 9 (MMP-9) in extracellular space. Some inflammatory cytokines such as. interleukin1 (IL-1), interlukin-6 (IL-6), and tumor necrosis factor-α (TNFα) can be involved in osteoclast differentiation and function ([@B34]--[@B37]). In normal condition Bone formation (by osteoblasts) and resorption (by osteoclasts) are in balanced for bone mass maintenance ([@B34], [@B38], [@B39]).](fendo-11-00430-g0001){#F1}

An Overview on Osteoporosis: Imbalance Between Bone Formation and Resorption {#s3}
============================================================================

As a result of the aging process, reduction in osteoblast number, function, and longevity, lead to bone formation decreasing However, bone resorption is exceeded due to sex hormones defection. Accordingly, individuals are predisposed to osteoporosis and osteoporotic bone fractures ([@B74]--[@B77]). In fact, osteoporotic bones due to low bone mass are fragile and brittle. The compression fractures of the vertebrae and traumatic fractures of the femoral neck and the wrist are the main issues of osteoporosis. Nevertheless, the hip fractures due to their burden are more considerable and need more attention. It is estimated that by 2050 the number of hip fractures will be more than 6 million and almost the 75% of them will be occurred in the developing countries ([@B9]). Osteoporosis can be followed by various complications and disorders. Usually, low levels of estrogen in post-menopausal women is the most well-known factor ([@B78]). In clinical diagnostic techniques of osteoporosis, dual x-ray absorptiometry \[DXA\] is approved as a gold standard approach to diagnose and follow the osteoporosis by calculating BMD ([@B79]). The WHO defines a set of categories to diagnose osteopenia and osteoporosis. These guidelines are based on T-score and Z-score. T-score shows the number of standard deviations above or below the mean reference value for 30 year-old healthy adults. However, Z-score measures the BMD regards to the average BMD of the same age and gender ([@B80]). According to the guidelines, a score above −1 is considered normal, a score between −1 and −2.5 indicates osteopenia, and a score below −2.5 portends the osteoporosis ([@B79]). Hereupon, for individuals with osteoporosis diagnosed, various treatments are recommended to increase the quality of life and decrease the economic burden on health care system ([@B1]).

Current Treatments and Limitations {#s4}
==================================

Osteoporosis cannot be cured but some of the pharmacological and non-pharmacological treatment approaches can manage it ([Table 1](#T1){ref-type="table"}) through the strengthening the bones and preventing the consequent fractures. In this context, using bisphosphonates, selective estrogen receptor modulators (SERMs), teriparatide, denosumab, calcitonin, and hormone replacement therapy (HRT) are the approved methods as the pharmacological treatments for osteoporosis ([@B94]). Additionally, some of the non-pharmacological treatments are including nutritional therapy, physical exercises, vertebroplasty, and kyphoplasty. Despite the preventive and therapeutical effects of these treatments, there are some limitations and side effects around using them. Hence, it is needed to apply new and more effective approaches with fewer side effects for osteoporosis management.

###### 

Some of the pharmacological and non-pharmacological treatments for osteoporosis ([@B81]--[@B93]).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Treatment**                            **Positive effects**                                                                                                 **Side effects/limitations**                                                                                                                                     **Type of treatment**
  ---------------------------------------- -------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------
  Bisphosphonates                          \- Can decrease both hip and spine fracture risk through maintaining the bone mineral density                        \- Osteonecrosis of jaw\                                                                                                                                         Pharmacological
                                                                                                                                                                - Gastrointestinal and renal discomfort\                                                                                                                         
                                                                                                                                                                - Atypical femoral fractures\                                                                                                                                    
                                                                                                                                                                - Acute influenza-like illness                                                                                                                                   

  Teriparatide                             \- As a recombinant parathyroid hormone can be used to stimulate osteoblasts to reconstruct the osteoporotic bone\   \- Inflammation of the nose\                                                                                                                                     Pharmacological
                                           - Can improve the bone mineral density and the bone architecture\                                                    - Diarrhea\                                                                                                                                                      
                                           - Considered as an impressive agent to decrease the vertebral, non-vertebral, and hip fracture risks                 - Constipation\                                                                                                                                                  
                                                                                                                                                                - Joint Pain                                                                                                                                                     

  Hormone replacement therapy              \- Safe and cost-benefit approach with positive effects on preventing the vertebral and non-vertebral fractures      \- Cardiovascular, thromboembolic, and gallbladder discomforts, breast and endometrial cancers                                                                   Pharmacological

  Selective estrogen receptor modulators   \- Can be a good choice to prevent the number of hormone replacement therapy related complications\                  \- Have some limitations in preventing non-vertebral fractures and also have extra-skeletal side effects                                                         Pharmacological
                                           - Can improve the bone mass and reduce the fracture risk                                                                                                                                                                                                                              

  Physical exercises                       \- Can lead to bone loss reduction\                                                                                  \- Some types of physical exercises such as abdominal sit-ups or loaded forward flexion of the spine can increase the risk of the spine compression fractures.   Non-pharmacological
                                           - Can conserve remain bone tissue\                                                                                                                                                                                                                                                    
                                           - Can reduce the risk of bone fractures caused by falls                                                                                                                                                                                                                               

  Vertebroplasty                           \- Can relieve symptoms associated with vertebral compression fractures                                              \- May lead to spinal cord or nerve root injury\                                                                                                                 Non-pharmacological
                                                                                                                                                                - May lead to infection\                                                                                                                                         
                                                                                                                                                                - May lead to pulmonary embolus                                                                                                                                  

  Kyphoplasty                              \- Can relieve symptoms associated with vertebral compression fractures                                              \- May lead to cement leaks\                                                                                                                                     Non-pharmacological
                                                                                                                                                                - May lead to infection\                                                                                                                                         
                                                                                                                                                                - May occur balloon rupture                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell Therapy as a Novel Approach {#s5}
================================

The clinical demand for new therapeutic methods has been led to progress in stem cell therapy and regenerative medicine ([@B23], [@B95]). In other words, stem cell-based therapies are becoming increasingly important in treatment of chronic and long-lasting diseases ([@B96], [@B97]). However, there are several parameters which need to be optimized for maximizing stem cell-based therapies potential. In this context, various basic and clinical studies related to the effects of stem cell-based therapies on diseases with no definite treatments were performed ([@B22], [@B98], [@B99]). Accordingly, some investigations were also conducted in the field of stem cell therapy for osteoporosis. Herein, the application of different types of stem cells including embryonic, induced pluripotent, and MSCs along with their secretion factors were evaluated to treat osteoporosis ([@B100]--[@B102]).

Mechanism of Stem Cells Function in Bone Remodeling and Osteoporosis {#s6}
====================================================================

Osteoporosis is a multifactorial disorder with endogenous and exogenous components ([@B103], [@B104]). Cell-based regenerative medicine can be invaluable in osteoporosis treatment through bone resorption modulation, fractures susceptibility reduction, and lost mineral density enhancement. These are possible by increasing the number of progenitor stem cells and improve the function of stem cells (proliferation and differentiation into bone-forming cells) ([@B20], [@B102], [@B105], [@B106]). Since the bone tissue repair cascade can be controlled by local signals from various cytokines and growth factors through the inducing osteoprogenitor cells migration, differentiation, proliferation, revascularization, and extracellular matrix production ([@B56], [@B107], [@B108]), stem cells (especially MSCs) can support bone regeneration by secreting bioactive molecules such as IGF-1, TGF-β, vascular endothelial growth factor (VEGF), angiogenin, hepatocyte growth factor (HGF), IL-6, and etc. ([@B56], [@B109]--[@B113]). On the other hand, MSCs derived exosomes are other factors which their effects on preventing the bone loss and promoting bone remodeling processes (during osteogenesis, osteoclastogenesis, and angiogenesis) have been demonstrated *in vitro* and *in vivo* ([@B114]--[@B116]).

Embryonic, Induced Pluripotent, and Embryonic Like Stem Cells in Osteoporosis {#s7}
=============================================================================

Although particular protocols are demanded to direct differentiation of embryonic stem cells (ESCs) (from the inner cell mass of a blastocyst) and induced pluripotent stem cells (iPSCs) (embryonic--like stem cells reprogrammed from adult cells) toward the osteoblasts and osteocyte-like cells (bone-forming cells), some of investigations were shown that application of these most known pluripotent stem cells in osteoporosis treatment is limited due to ethical concerns ([@B20], [@B117], [@B118]). Recently, implementation of very small embryonic-like stem cells (VSELs) (non-hematopoietic pluripotent cells that express embryonic characteristics markers and stored during the organogenesis in organs and tissues) as the autologous treatment for decreasing the aging processes which lead to osteoporosis and other skeletal disorders is taken into consideration. However, according to some studies, VSELs population will decrease with aging ([@B20], [@B119], [@B120]).

Mesenchymal Stem Cells in Osteoporosis {#s8}
======================================

In osteoporosis, there is a reduction in endogenous MSCs function (proliferation, differentiation, and consequently bones formation). Accordingly, they are the most common types of stem cells investigated in osteoporosis treatment. In this respect, examples of MSCs transplantation in osteoporotic animal models and humans were shown in [Table 2](#T2){ref-type="table"}. MSCs are an important example of non-hematopoietic stem cells with less ethical concerns and numerous advantages for clinical usage, containing accessibility and ease of harvesting, immunosuppressive outcomes, multi-lineal differentiation ability (especially ability to differentiate into osteoblasts), and any possibility of malignant transformation ([@B21], [@B131]--[@B133]). Additionally, as a subset of stromal stem cells, they can be obtained from various tissue sources. Bone marrow derive MSCs (BM-MSCs) with high osteogenic differentiation capability are the most common types of MSCs which have been used for osteoporosis ([@B20], [@B24], [@B134]--[@B136]). Herein, accumulating evidence indicates that alternation in the molecular mechanisms which modulate osteoblast differentiation in MSCs will make the MSC therapies reliable and more effective for osteoporosis ([@B105], [@B137]--[@B139]). While in accordance with other studies the most therapeutic impressions of MSCs are due to their supporting regenerative microenvironment ability and paracrine effects rather than their differentiation ability. In other words, MSC transplantation might open a new chapter in osteoporosis treatment specifically through paracrine effects ([Figure 2](#F2){ref-type="fig"}) ([@B140]--[@B143]).

###### 

Examples of MSCs transplantation in osteoporotic animal models and humans.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **UC-MSC**                                  **ADMSC**                                                                                                        **BM-MSC**                                                                                                        **Stem cell type**
  ------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- --------------------
  −30 ovariectomized rats (2018) ([@B121])\   −30 ovariectomized rats (2018) ([@B124])\                                                                        −60 estrogen deficiency-induced osteoporotic\                                                                     Animal Study
  - 30 Wistar rats (2018) ([@B122])\          - 22 SAMP6 mice (2014) ([@B125])\                                                                                - C57/BL6 mice (2017) ([@B127])\                                                                                  
  - 20 e Balb/c nude mice (2008) ([@B123])    - 27 Balb/c nude mice (2011) ([@B126])                                                                           - 22 goats (2012) ([@B128])\                                                                                      
                                                                                                                                                               - 25 isogenic Wistar rats (2010) ([@B129])\                                                                       
                                                                                                                                                               - 30 number of rabbits (2006) ([@B130])                                                                           

  --                                          8 participants (2012--2014) [ClinicalTrials.gov](https://ClinicalTrials.gov) Identifier: NCT01532076 ([@B105])   10 participants (2015--2018) [ClinicalTrials.gov](https://ClinicalTrials.gov) Identifier: NCT02566655 ([@B105])   Clinical Trial
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![Paracrine Effects of Mesenchymal Stem Cells in Bone Regeneration. Mesenchymal stem cells (MSCs) can participate in bone regeneration by secreting bioactive molecules such as Insulin-like growth factor 1 (IGF-1), Transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), interleukin−6 (IL-6), and fibroblast growth factor (FGF) ([@B140]--[@B143]).](fendo-11-00430-g0002){#F2}

Conclusion and Future Directions {#s9}
================================

The burden of osteoporosis is raised by an increase in the proportion of older persons in societies. Routine treatments only alleviate the symptoms partially. Hence, they are not sufficient enough. Therein, regenerative medicine sheds light on the treatment of osteoporosis. Specifically, MSCs therapy is the most common technique of regenerative medicine in osteoporosis treatment. Moreover, using small molecules (e.g., PTH and oxytocin) which employ endogenous stem cells for osteoporosis treatment will be intertwined in future management ([@B20], [@B144]). Despite the many investigations in cell therapy for osteoporosis, further studies are still demanded to fulfill the gaps including the definite differentiation fate and biodistribution of transplanted stem cells. On the other hand, in accordance with growing advances in osteoporosis personalized medicine (the applying of specific medical treatment based on the individual characteristics of each patient), it is required to identify the important bone loss signaling pathways and genes involved in each individual ([@B145]--[@B148]). In this context, metabolomics evaluation (the principled investigation of small molecules profile in a biological system) ([@B149], [@B150]) also can be helpful to the osteoporosis diagnosis of individuals with a genetic capacity ([@B151], [@B152]). Additionally, the biomedical using of exosomal based treatments will present novel approaches in clinical practice for osteoporosis ([@B116]).
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BMD

:   Bone Mineral Density

WHO

:   World Health Organization

MSCs

:   Mesenchymal Stem Cells

Runx2

:   Runt-related transcription factor 2

OSX

:   Osterix

Atf4

:   Activating transcription factor 4

AP-1

:   Activator Protein 1

FGFs

:   Fibroblast Growth Factors

TGF-β

:   Transforming Growth Factor β

IGF-1

:   Insulin-like Growth Factor 1

BMP

:   Bone Morphogenetic Protein

PTH

:   Parathyroid hormone

MMP-9

:   Matrix Metallopeptidase 9

M-CSF

:   Monocyte/Macrophage Colony-Stimulating Factor

OPG

:   Osteoprotegerin

HSC

:   Hematopoietic Stem Cells

IL-1

:   Interleukin1

Il-6

:   Interleukin 6

TNFα

:   Tumor Necrosis Factor α

DXA

:   Dual X-ray Absorptiometry

SERMs

:   Selective Estrogen Receptor Modulators

IV

:   Intravenous

HRT

:   Hormone Replacement Therapy

VEGF

:   Vascular Endothelial Growth Factor

HGF

:   Hepatocyte Growth Factor

ESCs

:   Embryonic Stem Cells

iPSCs

:   induced Pluripotent Stem Cells

VELs

:   Very small Embryonic-Like stem cells

BM- MSCs

:   Bone Marrow Mesenchymal Stem Cells.
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